Page last updated: 2024-08-23

razoxane and prednisone

razoxane has been researched along with prednisone in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19902 (40.00)18.7374
1990's1 (20.00)18.2507
2000's0 (0.00)29.6817
2010's2 (40.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Das, S; Freedman, LS; Garrett, MJ; Smith, JD1
Vogel, CL1
Ben-Yehuda, D; Lossos, IS1
Antonelli, A; Carpi, A; Cervetti, G; Fallahi, P; Franzoni, F; Galetta, F; Petrini, M; Regoli, F; Santoro, G; Tocchini, L1
Cunningham, D; Hawkes, EA; Okines, AF; Plummer, C1

Reviews

1 review(s) available for razoxane and prednisone

ArticleYear
Management of Kaposi's sarcoma. Chemotherapy I.
    Antibiotics and chemotherapy, 1981, Volume: 29

    Topics: Alkylating Agents; Antibiotics, Antineoplastic; Carmustine; Dactinomycin; Humans; Immunosuppressive Agents; Prednisone; Razoxane; Sarcoma, Kaposi; Vinca Alkaloids

1981

Trials

1 trial(s) available for razoxane and prednisone

ArticleYear
In vitro and in vivo study on the antioxidant activity of dexrazoxane.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2010, Volume: 64, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Bleomycin; Chromans; Cyclophosphamide; Cytarabine; Epirubicin; Etoposide; Female; Free Radical Scavengers; Glutathione; Humans; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Prednisone; Razoxane; Time Factors; Uric Acid; Vincristine

2010

Other Studies

3 other study(ies) available for razoxane and prednisone

ArticleYear
Long term experience with combination chemotherapy in advanced Hodgkin's disease.
    Clinical oncology, 1977, Volume: 3, Issue:2

    Topics: Adult; Antineoplastic Agents; Bleomycin; Drug Therapy, Combination; Female; Hodgkin Disease; Humans; Leukemia; Lomustine; Male; Mechlorethamine; Middle Aged; Mutagens; Neoplasms, Multiple Primary; Oxymetholone; Prednisone; Pregnancy; Procarbazine; Razoxane; Teratogens; Vinblastine; Vincristine

1977
Cutaneous and subcutaneous necrosis following dexrazoxane-CHOP therapy.
    The Annals of pharmacotherapy, 1999, Volume: 33, Issue:2

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cardiovascular Agents; Cyclophosphamide; Doxorubicin; Fatal Outcome; Female; Humans; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Necrosis; Prednisone; Razoxane; Skin; Vincristine

1999
Cardiotoxicity in patients treated with bevacizumab is potentially reversible.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011, Jun-20, Volume: 29, Issue:18

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Clinical Trials, Phase II as Topic; Cyclophosphamide; Deoxycytidine; Dose-Response Relationship, Drug; Doxorubicin; Drug Labeling; Early Termination of Clinical Trials; Epirubicin; Female; Fluorouracil; Heart Failure; Humans; Lymphoma, Large B-Cell, Diffuse; Meta-Analysis as Topic; Paclitaxel; Prednisone; Razoxane; Remission, Spontaneous; Rituximab; Trastuzumab; Vincristine

2011